Pfizer (PFE) Revenue — Quarter Ended Dec 31, 2024
Revenue for the reporting quarter increased relative to both the immediately preceding quarter and the same period one year earlier. The company's filing notes a focus on working capital efficiencies and liquidity management.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 Q4
Revenue for the reporting quarter increased relative to both the immediately preceding quarter and the same period one year earlier. The company's filing notes a focus on working capital efficiencies and liquidity management.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$17.8B
Revenue reported for this quarter.
Quarter-over-quarter
+0.3%
Change from the immediately preceding quarter.
Year-over-year
+21.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$63.6B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $14.9B | -19.5% |
| Jun 30, 2024 | $13.3B | +2.1% |
| Sep 29, 2024 | $17.7B | +31.2% |
| Dec 31, 2024 | $17.8B | +21.9% |
Revenue performance
Revenue rose compared with the prior quarter, extending the upward trajectory seen in the preceding period.
Quarterly comparison
When measured against the same quarter of the previous year, revenue was higher, reflecting a substantial year-over-year gain.
What to watch
The filing highlights ongoing efforts to optimize working capital, including accounts receivable and inventory.